Inter-tumor heterogeneity

Mike Cusnir, Ludmila Cavalcante

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.

Original languageEnglish
Pages (from-to)1143-1145
Number of pages3
JournalHuman Vaccines and Immunotherapeutics
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Neoplasms
Biomarkers
Mutation
Therapeutics
Research

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Inter-tumor heterogeneity. / Cusnir, Mike; Cavalcante, Ludmila.

In: Human Vaccines and Immunotherapeutics, Vol. 8, No. 8, 01.08.2012, p. 1143-1145.

Research output: Contribution to journalArticle

Cusnir, M & Cavalcante, L 2012, 'Inter-tumor heterogeneity', Human Vaccines and Immunotherapeutics, vol. 8, no. 8, pp. 1143-1145. https://doi.org/10.4161/hv.21203
Cusnir, Mike ; Cavalcante, Ludmila. / Inter-tumor heterogeneity. In: Human Vaccines and Immunotherapeutics. 2012 ; Vol. 8, No. 8. pp. 1143-1145.
@article{36c14d17ac86423780e2c2604aa10591,
title = "Inter-tumor heterogeneity",
abstract = "Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.",
author = "Mike Cusnir and Ludmila Cavalcante",
year = "2012",
month = "8",
day = "1",
doi = "10.4161/hv.21203",
language = "English",
volume = "8",
pages = "1143--1145",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Inter-tumor heterogeneity

AU - Cusnir, Mike

AU - Cavalcante, Ludmila

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.

AB - Advances in the molecular study of cancer have focused on biomarkers in the setting of tumor-driving mutations within the great heterogeneity of the tumor genomic landscape. It is clearly recognized now that even two tumors originating from the same organ even if histological they appear similar their behavior and response to therapy can be different. These findings have increased interest and research to find truly prognostic and predictive biomarkers to serve as tools in better assessing the natural course of disease and response to treatments in the hope of truly individualizing cancer therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=84866131656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866131656&partnerID=8YFLogxK

U2 - 10.4161/hv.21203

DO - 10.4161/hv.21203

M3 - Article

C2 - 22854659

AN - SCOPUS:84866131656

VL - 8

SP - 1143

EP - 1145

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 8

ER -